Abstract
BACKGROUND: Eosinophilic pustular folliculitis (EPF) is a rare chronic inflammatory skin disease characterized by eosinophilic infiltration and recurrent sterile pustules. Current treatments are often ineffective, and the disease frequently relapses. METHODS: We report a case of a 71-year-old female with severe EPF and a 17-year history of recurrent pruritic papulopustular eruptions. Dupilumab was administered subcutaneously with a 600 mg loading dose followed by 300 mg every two weeks over two treatment courses, separated by a five-month loss to follow-up. RESULTS: After dupilumab therapy, the patient's skin lesions completely resolved, accompanied by a marked decrease in peripheral eosinophil counts. During a 2-year follow-up, no recurrence was observed. CONCLUSION: Dupilumab demonstrated significant efficacy and safety in this severe and refractory EPF case, resulting in long-term remission without relapse, and highlighting its potential as a novel treatment option for EPF.